Part B Reforms: MedPAC Moving Forward With 'Drug Value Program' Proposal
Even under most ambitious timeline, new competitive-bidding approach would not start before 2022 – and that assumes Congress has appetite for the legislation with an already full plate of health care work to do. But new ideas in Part B are worth watching.
You may also be interested in...
In its June report to Congress, the Medicare Payment Advisory Commission expands upon previous recommendations for establishing a binding arbitration process to control drug prices in Medicare.
Medicare Payment Advisory Commission executive director Mathews suggests at April 30 hearing that manufacturers should bear more “liability” for catastrophic coverage in Medicare Part D.
In comments on Medicare Part B International Pricing Index, Medicare Payment Advisory Commission notes concerns with international reference pricing and advises a stronger role for private sector vendors to generate savings.